Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo

International Journal of Cancer

Volumn 129, Issue 12, 2011, Pages 2958-2965

  Segerström, Lova ^a   Baryawno, Ninib ^a   Sveinbjörnsson, Baldur ^a,b   Wickström, Malin ^a   Elfman, Lotta ^a   Kogner, Per ^a   Johnsen, John Inge ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

experimental models; MYCN; neuroblastoma; PI3K Akt; small molecule inhibitors

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P55; PROTEIN P85; S6 KINASE; CCND1 PROTEIN, HUMAN; FURAN DERIVATIVE; MTOR PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; OSU03013; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRUVATE DEHYDROGENASE (ACETYL TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLIN D1; FURANS; HUMANS; MICE; MICE, NUDE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84855183683     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26268     Document Type: Article

References (33)

1. Johnsen JI, Kogner P, Albihn A, Henriksson MA,. Embryonal neural tumors and cell death. Apoptosis 2009; 14: 424-38.
2. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16. (Pubitemid 37328872)
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL,. Neuroblastoma. Lancet 2007; 369: 2106-20. (Pubitemid 46935947)
4. Engelmann J,. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-62.
5. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Eksborg S, Sveinbjörnsson B, Kogner P,. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008; 27: 2910-22. (Pubitemid 351620441)
6. Opel D, Poremba C, Simon T, Debatin K-M, Fulda S,. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007; 67: 735-45. (Pubitemid 46192214)
7. Cully M, You H, Levine AJ, Mak TW,. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-92. (Pubitemid 43292562)
8. Garcia-Echeverria C, Sellers WR,. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008; 27: 5511-26.
9. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS,. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004; 64: 4309-18. (Pubitemid 38802438)
10. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA,. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67: 7960-65. (Pubitemid 47395125)
11. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA,. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 206; 9: 341-49.
12. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S, Berhard EJ,. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008; 68: 5915-23.
13. Westhoff MA, Kandenwein JA, Karl S, Vellanki SH, Braun V, Eramo A, Antoniadis G, Debatin KM, Fulda S,. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 2009; 28: 3586-96.
14. Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, Fulda S,. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 2011; 30: 494-503.
15. Baryawno N, Sveinbjörnsson B, Eksborg S, Chen CS, Kogner P, Johnsen JI,. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 2010; 70: 266-76.
16. Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, Faraq SS,. OSU03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007; 13: 4750-58. (Pubitemid 47294781)
17. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen CS, Byrd JC,. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 2005; 105: 2504-09. (Pubitemid 40387052)
18. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandva AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P,. OSU03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2005; 70: 589-603. (Pubitemid 44092320)
19. Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee Wc, Feng WC, Chen CS, Kuo ML, Cheng AL,. OSU03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res 2008; 68: 9348-57.
20. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, Grotzer MA, Arcaro A,. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008; 14: 1172-81. (Pubitemid 351302566)
21. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI,. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 2006; 118: 2584-93.
22. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA,. Inhibition of phosphatidylinositol 3-kinase destabilizes MYCN protein and blocks malignant progression in neuroblastoma. Cancer Res 2006; 66: 8139-46. (Pubitemid 44299181)
23. Baryawno N, Sveinbjörnsson B, Kogner P, and, Johnsen JI,. Medulloblastoma: a disease with disorganized developmental signaling cascades. Cell Cycle 2010; 9: 2548-54.
24. Grimmer MR, Weiss WA,. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 2006; 18: 634-38. (Pubitemid 44747156)
25. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N,. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008; 14: 458-70.
26. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Kanopleva A, Andreff M, Nakakuma H,. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008; 22: 1728-36.
27. Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S,. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 2008; 68: 8361-68.
28. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA,. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010; 147: ra81.
29. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y,. Disruption of cooperation between Ras and MYCN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005; 11: 4321-30. (Pubitemid 40825619)
30. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ,. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004; 96: 46-55. (Pubitemid 38180959)
31. Li Z, Tan F, Liewehr DJ, Steinberg SM,., Thiele CJ,. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst 2010; 102: 758-70.
32. Workman P, Clarke PA, Guillard S, Raynaud FI,. Drugging the PI3 kinome. Nat Biotechnol 2006; 24: 794-796. (Pubitemid 44086618)
33. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, Prescott AR, Lucocq JM, Alessi DR,. Essential role of PDK1 in regulating cell size and development in mice. EMBO J 2002; 21: 3728-38. (Pubitemid 34787046)